Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
Healthcare
$5.86 -1.17%
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
52W Low $6.23High $16.44
Volume 3.08M
Average 3.00M
Balance Sheet
Inspect the capital base behind the business.
Assets
$808.06M
FY 2025 · Annual
+76.5% YoYLiabilities
$153.75M
FY 2025 · Annual
+7.8% YoYEquity
$654.31M
FY 2025 · Annual
+107.5% YoYBalance Sheet
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 21.14M | 21.33M | 26.18M | 32.39M | 30.65M |
| Inventory | 1.25M | 1.97M | 2.31M | 3.04M | 3.56M |
| Other Current Assets | 0 | 4.03M | 7.94M | 13.46M | 10.86M |
| Total Current Assets | 191.3M | 129.63M | 232.24M | 440.99M | 782.13M |
| Property, Plant & Equipment (Net) | 11.82M | 17.9M | 18.21M | 15.33M | 24.31M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 1.61M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.76M | 1.76M | 1.61M | 1.61M | 0 |
| Total Non-current Assets | 13.59M | 19.66M | 19.83M | 16.95M | 25.93M |
| Total Assets | 204.89M | 149.29M | 252.06M | 457.94M | 808.06M |
| Account Payables | 4.59M | 5.12M | 4.39M | 4.18M | 4.15M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.82M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 576K | 255K | 128K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 25.86M |
| Total Current Liabilities | 26.34M | 31.4M | 34.9M | 41.35M | 50.81M |
| Long-term Debt | 51.44M | 54.01M | 74.93M | 68.51M | 74.15M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 13M | 13.39M | 14.14M | 14M | 14M |
| Other Non-current Liabilities | 20.19M | 6.44M | 30.1M | 13.39M | 11.98M |
| Total Non-current Liabilities | 90.55M | 82.52M | 126.03M | 101.24M | 102.94M |
| Total Liabilities | 116.89M | 113.91M | 160.93M | 142.59M | 153.75M |
| Common Stock | 8K | 8K | 12K | 16K | 22K |
| Retained Earnings | (545.8M) | (616.84M) | (697.58M) | (891.08M) | (1.16B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 88M | 35.38M | 91.13M | 315.34M | 654.31M |
| Total Debt | 58.98M | 64.28M | 83.39M | 75.78M | 79.78M |
| Net Debt | (105.18M) | (38.02M) | (112.42M) | (316.32M) | (657.28M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $666.7M |
| Receivables | $24.3M |
| Inventory | $3.7M |
| Other Current | $11.2M |
| Total Current Assets | $706.0M |
| PP&E (Net) | $24.9M |
| Long-term Investments | $1.6M |
| Other Non-current | -$1 |
| Total Non-current Assets | $26.5M |
| Total Assets | $732.5M |
Analysis
Selected assets total $732.5M for Latest. The largest visible component is Cash & Equivalents at $666.7M, about 91.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 |
How much cash does OCUL have?
Ocular Therapeutix, Inc. (OCUL) reported $737.06M in cash and equivalents in fiscal 2025.
How much debt does OCUL carry?
Ocular Therapeutix, Inc. (OCUL) reported $79.78M of total debt, with net debt of -$657.28M.
Continue the stock analysis
Jump to another research area for this company.